Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC cut its holdings in Editas Medicine, Inc. (NASDAQ:EDIT) by 10.2% during the 3rd quarter, Holdings Channel reports. The firm owned 117,639 shares of the company’s stock after selling 13,310 shares during the period. Los Angeles Capital Management LLC’s holdings in Editas Medicine were worth $401,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of EDIT. Russell Investments Group Ltd. grew its position in shares of Editas Medicine by 147.4% in the first quarter. Russell Investments Group Ltd. now owns 12,838 shares of the company’s stock valued at $95,000 after purchasing an additional 7,648 shares during the last quarter. Vanguard Group Inc. boosted its position in Editas Medicine by 1.1% during the first quarter. Vanguard Group Inc. now owns 8,555,597 shares of the company’s stock worth $63,483,000 after acquiring an additional 93,740 shares during the last quarter. Shell Asset Management Co. boosted its position in Editas Medicine by 33.5% during the first quarter. Shell Asset Management Co. now owns 87,967 shares of the company’s stock worth $653,000 after acquiring an additional 22,083 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in Editas Medicine during the first quarter worth approximately $72,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Editas Medicine by 16.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,704 shares of the company’s stock worth $369,000 after acquiring an additional 7,174 shares during the last quarter. 71.90% of the stock is currently owned by institutional investors and hedge funds.

Editas Medicine Trading Down 4.0 %

Shares of EDIT stock opened at $2.66 on Monday. The company’s fifty day simple moving average is $3.33 and its 200-day simple moving average is $4.38. Editas Medicine, Inc. has a 52 week low of $2.59 and a 52 week high of $11.69. The company has a market cap of $219.58 million, a PE ratio of -1.04 and a beta of 2.01.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Monday, November 4th. The company reported ($0.75) EPS for the quarter, meeting analysts’ consensus estimates of ($0.75). Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $3.93 million. During the same quarter last year, the firm posted ($0.55) EPS. The business’s revenue for the quarter was down 98.9% compared to the same quarter last year. Equities research analysts expect that Editas Medicine, Inc. will post -2.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EDIT has been the topic of a number of analyst reports. Stifel Nicolaus decreased their target price on shares of Editas Medicine from $17.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. Wells Fargo & Company decreased their target price on shares of Editas Medicine from $9.00 to $7.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Barclays decreased their target price on shares of Editas Medicine from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 5th. Chardan Capital restated a “buy” rating and set a $12.00 target price on shares of Editas Medicine in a research report on Tuesday, November 5th. Finally, Truist Financial decreased their price target on shares of Editas Medicine from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.08.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.